Sergio Senar

Employment

• drTarget CEO
  2018 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (10)

• From Infection to Oncology: AI-Assisted Drug Repurposing Uncovers Anti-Infective and Excipient-Class Compounds as PPAR-α-Linked Anticancer Agents
  Cancers 2026 DOI: 10.3390/cancers18193231
  +Save
• Cross-Database Characterization of Flavonoids and Phenolic Acids: Integrating Drug-likeness Metrics, Molecular Interactions, and Dietary Sources
  Molecules 2026 DOI: 10.3390/molecules31040728
  +Save
• Evidence for the druggability of aldosterone targets in heart failure: A bioinformatics and data science-driven decision-making approach
  Lucas Salgado Rezende de Mendonça, Sergio Senar, Luana Lorena Moreira +4 more
  Computers in Biology and Medicine 2024 DOI: 10.1016/j.compbiomed.2024.108124
  +Save
• Multiplatform-Integrated Identification of Melatonin Targets for a Triad of Psychosocial-Sleep/Circadian-Cardiometabolic Disorders
  International Journal of Molecular Sciences 2023 DOI: 10.3390/ijms24010860
  +Save
• PS-P02-1: MACHINE LEARNING PREDICTS MELATONIN TARGETS ON THE PSYCHOSOCIAL STRESS-SLEEP/CIRCADIAN-CARDIOMETABOLIC DISORDERS TRIAD
  Journal of Hypertension 2023 DOI: 10.1097/01.hjh.0000915164.40169.23
  +Save
• Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades
  Journal of Medicinal Chemistry 2022 DOI: 10.1021/acs.jmedchem.1c01883
  +Save
• Implication of type 4 NADPH oxidase (NOX4) in tauopathy
  Redox Biology 2022 DOI: 10.1016/j.redox.2021.102210
  +Save
• Cardioprotective Melatonin: Translating from Proof-of-Concept Studies to Therapeutic Use
  International Journal of Molecular Sciences 2019 DOI: 10.3390/ijms20184342
  +Save
• High Throughput Screening Assay to Identify Modulators of IL-17 Expression
  Combinatorial Chemistry & High Throughput Screening 2018 DOI: 10.2174/1386207320666170602091308
  +Save
• Identification and Characterization of Novel NMDA Receptor Antagonists Selective for NR2A- over NR2B-Containing Receptors
  The Journal of Pharmacology and Experimental Therapeutics 2010 DOI: 10.1124/jpet.110.172544
  +Save